Cryoport Inc.

We’re thrilled to celebrate Mesoblast Limited's ($MESO) historic FDA approval of RYONCIL®, the first mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease (SR-aGvHD). Cryoport, Inc. ($CYRX) is honored to play a role in Enabling the Future of Medicine by supporting Mesoblast with our advanced temperature-controlled supply chain solutions. This approval marks a significant achievement in advancing life-saving therapies for those in need.  

Cryoport Inc. ($CYRX) is honored to receive the Marketing Team of the Year award, presented by Life Science Sales and Marketing Awards (LSSM)! This achievement is a testament to the team’s creativity, resourcefulness, and passion in delivering outstanding marketing campaigns yielding impactful results.  #MarketingExcellence #AwardWinningTeam #MarketingTeamoftheYear

We're excited to share this important discussion on overcoming supply chain bottlenecks in cell and gene therapy, featuring Cryoport Inc. ($CYRX) subsidiary, Cryoport Systems. From sourcing high-quality starting materials to navigating the complexities of therapy delivery, this webinar offers strategies that drive efficiency and innovation across the entire supply chain.

Cryoport, Inc. ($CYRX) is proud to announce the opening of the newest Cryoport Systems IntegriCell™ Center of Excellence in Villers-le-Bouillet, Belgium. This GMP-compliant facility is dedicated to advanced cryopreservation of leukapheresis starting materials, supporting the clinical and commercial cell therapy programs of our clients around the world. https://lnkd.in/gjrHvEwf #CellTherapy #Cryopreservation #IntegriCell #SupplyChainSolutions

Cryoport, Inc. ($CYRX) today announced financial results for Q3 and the first nine months (9M) of 2024. In addition to supporting a record total of 691 global clinical trials, we are pleased to highlight the continued robust growth in our Life Sciences Services business, including an increase in BioStorage/BioServices revenue of 12% as compared to Q3-23 alongside a substantial improvement in gross margin to 46% for our services business. The full financial results are available on our website at cryoportinc.com. 

Our Q&A conference call discussing the Cryoport, Inc. ($CYRX) third quarter 2024 financial results will begin in 30 minutes at 5:00 p.m. ET. Investors and analysts are encouraged to join for real-time insights into Cryoport’s latest performance and growth initiatives. You can access the Q3 Quarterly Review document and information on joining the call at https://cryoportinc.com

Today, Cryoport, Inc. ($CYRX) will release its third quarter 2024 financial results after market close. Following the release, our leadership team will host a Q&A conference call at 5:00 p.m. ET. A Q3 Quarterly Review document will be available in advance by 4:15 p.m. ET. For full details, please visit our website: https://cryoportinc.com

Cryoport, Inc. ($CYRX) will announce its third quarter 2024 financial results tomorrow, November 7, after U.S. markets close. Following the release, we invite the investment community to join a Q&A conference call at 5:00 p.m. ET, where the management team will discuss financial performance and provide business updates. For details, please visit https://lnkd.in/gNxGaeQm

Congratulations to Allogene Therapeutics on receiving the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 in the treatment of adult patients with CD70 positive advanced or metastatic renal cell carcinoma. At Cryoport, Inc.($CYRX), we are honored to support companies like Allogene as they continue to innovate and push the boundaries of CAR T therapy.

Cryoport, Inc ($CYRX) extends heartfelt congratulations to Abeona Therapeutics on the resubmission of their Biologics License Application (BLA) for prademagene zamikeracel (pz-cel) to the U.S. FDA. This important step in the regulatory process signifies a promising potential treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). We are proud to Enable the Future of Medicine™ by supporting companies bringing innovative therapies to the forefront of patient care.